Midatech Appoints Dr Jim Phillips as Chief Executive Officer
News Oct 02, 2013
During this time he has accumulated considerable expertise in M&A and licensing deal origination and execution, which he now brings to the role of CEO of Midatech.
Dr Phillips joins Midatech from Healthcare Brands International Ltd (HBI), the UK consumer healthcare company, where he has been CEO since 2010. Between 2007 and 2012 he served as Non-executive Chairman of Prosonix Ltd, a specialty pharmaceutical company developing respiratory medicines using an innovative particle-engineering technology and approach.
Before joining HBI, Dr Phillips was CEO of Vantia Ltd., a pharmaceutical company developing novel, small molecule drugs. Prior to that he founded and served as CEO of Talisker Pharma until its acquisition by EUSA in 2006, upon which he became President of EUSA Pharma Europe and an Executive Board Member EUSA Pharma Inc. Dr Phillips has also held senior roles in drug and business development in Novartis and Johnson & Johnson.
Commenting on the appointment, Professor Thomas Rademacher, Chairman of Midatech said: “I am very pleased to welcome Jim to the Company as our new CEO. I have no doubt his senior management and commercial experience within the Biotechnology sector will help us sign the partnership deals and raise the funds we need to deliver the significant potential of our unique gold-nanoparticle technology.”
Dr Philips added: “I am excited to have joined Midatech at this crucial stage as it accelerates the development and commercialisation of its novel gold nanoparticle technology. With its potential to greatly improve the delivery of important drugs for the treatment of diabetes and various cancer types, as well as uses in medical diagnostics and imaging, I am confident that Midatech will generate significant growth and value over the next several years.”
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE